Prospective multicenter phase II clinical trial of FOLFIRI chemotherapy as a neoadjuvant treatment for colorectal cancer with multiple liver metastases
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Ji Yeon | - |
dc.contributor.author | Kim, Jin Soo | - |
dc.contributor.author | Beek, Moo Jun | - |
dc.contributor.author | Kim, Chang Nam | - |
dc.contributor.author | Choi, Won Jun | - |
dc.contributor.author | Park, Dong Kook | - |
dc.contributor.author | Namgung, Hwan | - |
dc.contributor.author | Lee, Sang Chul | - |
dc.contributor.author | Lee, Sang-Jeon | - |
dc.date.accessioned | 2021-08-12T00:45:55Z | - |
dc.date.available | 2021-08-12T00:45:55Z | - |
dc.date.issued | 2013-10 | - |
dc.identifier.issn | 2233-7903 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/13339 | - |
dc.description.abstract | Purpose: This study evaluated the efficacy of neoadjuvant chemotherapy combining 5-flurouracil/folinic acid with irinotecan (FOLFIRI) in colorectal multiple liver metastases regardless of resectability. Methods: Forty-four patients with multiple (at least two) colorectal liver metastases were enrolled at seven tertiary referral hospitals between May 2007 and September 2010. All patients received the FOLFIRI chemotherapeutic regimen. Response to chemotherapy was assessed after three cycles (6 weeks) and once more after six cycles (12 weeks) of treatment. Results: Objective response was noted in 27 patients (61.4%) and 4 patients (9.1%) had progressive disease. Of 44 patients, 10 patients (22.7%) underwent curative surgery (R0 resection) and 34 patients did not receive R0 resection. Grades 3 to 4 hematological toxicity was noted in 12 patients (27.3%) and grades 3 to 4 nonhematologic toxicity was identified in 5 patients (11.4%). Conclusion: FOLFIRI chemotherapy as a neoadjuvant chemotherapy for multiple colorectal liver metastases regardless of resectability demonstrated the possibility of R0 resection, high rate of objective response, and tolerable toxicities in this study. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.title | Prospective multicenter phase II clinical trial of FOLFIRI chemotherapy as a neoadjuvant treatment for colorectal cancer with multiple liver metastases | - |
dc.type | Article | - |
dc.identifier.doi | 10.4174/jkss.2013.85.4.154 | - |
dc.identifier.wosid | 000325056600002 | - |
dc.identifier.bibliographicCitation | Journal of the Korean Surgical Society, v.85, no.4, pp 154 - 160 | - |
dc.citation.title | Journal of the Korean Surgical Society | - |
dc.citation.volume | 85 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 154 | - |
dc.citation.endPage | 160 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001803438 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Surgery | - |
dc.relation.journalWebOfScienceCategory | Surgery | - |
dc.subject.keywordPlus | FOLINIC ACID | - |
dc.subject.keywordPlus | SYSTEMIC CHEMOTHERAPY | - |
dc.subject.keywordPlus | HEPATIC METASTASES | - |
dc.subject.keywordPlus | IRINOTECAN | - |
dc.subject.keywordPlus | RESECTION | - |
dc.subject.keywordPlus | 5-FLUOROURACIL | - |
dc.subject.keywordPlus | OXALIPLATIN | - |
dc.subject.keywordPlus | FLUOROURACIL | - |
dc.subject.keywordPlus | LEUCOVORIN | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordAuthor | Colorectal cancer | - |
dc.subject.keywordAuthor | Neoadjuvant therapy | - |
dc.subject.keywordAuthor | Metastasis | - |
dc.subject.keywordAuthor | Chemotherapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.